Beneficial effects of metformin treatment in hyperglycaemic patients affected by ischaemia with no obstructive coronary artery

Affiliations

¹ Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York City, NY 10461, USA.
² Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso 86100, Italy.
³ Casa di Cura 'Montevergine', Mercogliano (Avellino) 83013, Italy.
⁴ GVM Care & Research, Department of Cardiovascular Surgery, Anthea Hospital, 70100 Bari, Italy.
⁵ International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit and Department of Advanced Biomedical Sciences, University of Naples 'Federico II', 80131 Naples, Italy.
⁶ Department of Molecular Pharmacology, Einstein Institute for Aging Research, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine, New York City, NY 100461, USA.

Pasquale Mone et al. Cardiovasc Res. 2025.

. 2025 May 6;121(4):532-534.

doi: 10.1093/cvr/cvae269.

¹ Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein College of Medicine, New York City, NY 10461, USA.
² Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso 86100, Italy.
³ Casa di Cura 'Montevergine', Mercogliano (Avellino) 83013, Italy.
⁴ GVM Care & Research, Department of Cardiovascular Surgery, Anthea Hospital, 70100 Bari, Italy.
⁵ International Translational Research and Medical Education (ITME) Consortium, Academic Research Unit and Department of Advanced Biomedical Sciences, University of Naples 'Federico II', 80131 Naples, Italy.
⁶ Department of Molecular Pharmacology, Einstein Institute for Aging Research, Fleischer Institute for Diabetes and Metabolism (FIDAM), Einstein Institute for Neuroimmunology and Inflammation (INI), Albert Einstein College of Medicine, New York City, NY 100461, USA.

No abstract available

Conflict of interest statement

Conflict of interest: none declared.

1. Polyak A, Wei J, Gulati M, Merz NB. Clinical aspects of ischemia with no obstructive coronary artery disease (INOCA). Am Heart J Plus 2024;37:100352. - PMC - PubMed
1. Chiarito M, Sanz-Sanchez J, Piccolo R, Condello F, Liccardo G, Maurina M, Avvedimento M, Regazzoli D, Pagnotta P, Garcia-Garcia HM, Mehran R, Federici M, Condorelli G, Diez Gil JL, Reimers B, Ferrante G, Stefanini G. Safety of metformin continuation in diabetic patients undergoing invasive coronary angiography: the NO-STOP single arm trial. Cardiovasc Diabetol 2023;22:28. - PMC - PubMed
1. Kataoka Y, Nicholls SJ, Andrews J, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Puri R. Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysis. Cardiovasc Diagn Ther 2022;12:77–87. - PMC - PubMed
1. Luo F, Das A, Chen J, Wu P, Li X, Fang Z. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol 2019;18:54. - PMC - PubMed
1. Mohan M, Al-Talabany S, McKinnie A, Mordi IR, Singh JSS, Gandy SJ, Baig F, Hussain MS, Bhalraam U, Khan F, Choy AM, Matthew S, Houston JG, Struthers AD, George J, Lang CC. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J 2019;40:3409–3417. - PMC - PubMed